



(51) International Patent Classification:

C07D 487/04 (2006.01) *A61P 11/00* (2006.01)
A61K 31/5025 (2006.01) *A61P 25/00* (2006.01)
A61P 9/00 (2006.01) *A61P 27/02* (2006.01)

(21) International Application Number:

PCT/IB2015/055597

(22) International Filing Date:

23 July 2015 (23.07.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/033,684 6 August 2014 (06.08.2014) US
 62/157,129 5 May 2015 (05.05.2015) US

(71) Applicant: **PFIZER INC.** [US/US]; 235 East 42nd Street,
 New York, New York 10017 (US).

(72) Inventors: **CHAPPIE, Thomas Allen**; 59 Hemlock Hill
 Road, Carlisle, Massachusetts 01741 (US). **HAYWARD,
 Matthew Merrill**; 3 Pyrus Court, Old Lyme, Connecticut
 06371 (US). **HELAL, Christopher John**; 18 Elm Street,
 Mystic, Connecticut 06355 (US). **LACHAPPELLE, Erik
 Alphie**; 69 Richard Brown Drive, Uncasville, Connecticut
 06382 (US). **PATEL, Nandini Chaturbhai**; 34 Mary El-
 len Road, Waban, Massachusetts 02468 (US).
SCIABOLA, Simone; 109 River Street, Cambridge, Mas-
 sachusetts 02139 (US). **VERHOEST, Patrick Robert**; 23
 Calvin Road, Newton, Massachusetts 02460 (US).
YOUNG, Joseph Michael; 1 Hampshire Road, Madison,
 Connecticut 06443 (US).

(74) Agent: **OLSON, A. Dean**; Pfizer Worldwide Research &
 Development, Eastern Point Road MS8260-2141, Groton,
 Connecticut 06340 (US).

(81) Designated States (unless otherwise indicated, for every
 kind of national protection available): AE, AG, AL, AM,
 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
 BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
 PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
 SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
 kind of regional protection available): ARIPO (BW, GH,
 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
 TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
 TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
 LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
 SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
 GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a
 patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
 earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: IMIDAZOPYRIDAZINE COMPOUNDS



(57) Abstract: The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents R^1 , R^3 , R^6 , R^7 , and b are as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of preparing the compounds.

